drugset / Trial / NCT03889314

The DEtermining Statin Intolerance FOr Rosuvastatin (DESIFOR) Trial

NCT03889314 ↗

Phase 4 Unknown 25 enrolled Minneapolis Heart Institute Foundation
RandomizedCrossoverTriple-blindPrevention

Summary

This study will enroll patients who previously were not able to tolerate being on a statin medication due to muscle-related side effects. Research has shown that many people who have muscle symptoms on statin therapy do not experience the same side effects if they try it again later. This study is part of a larger effort to: * See how common it is for patients to still be intolerant of statin medication after trying it a second time; and * For those patients who do tolerate being on a statin after trying it a second time, see how common it is for them to still be taking the statin 3 months after completing the main part of the study. Patients who agree to participate will be given a 5 month randomly allocated supply of statin and placebo and track their symptoms weekly.

Timeline

Start
2019-04-26
Primary completion
2022-12-31
Completion
2022-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Rosuvastatin Small molecule 20 mg —